Table 2

Deregulated tyrosine kinases in hematological disorders

Fusion geneTranslocationDiseaseRef.
BCR-ABL t(9;22)(q34;q11)CML34 and 35
ETV6-ABL t(9;12)(q34;p13)ALL, Ph− CMLa4 and 36
ETV6-JAK2 t(9;12)(p24;p13)ALL, aCML5 and 37
ZNF198-FGFR1 t(8;13)(p11;q12)EMS7, 8, 38, and 39
FOP-FGFR1 t(6;8)(q27;p11)EMS40
ETV6-PDGFβR t(5;12)(q33;p13)CMML/aCML6
HIP1-PDGFβR t(5;7)(q33;q11)CMML12
CEV14-PDGFβR t(5;14)(q33;q32)AML13
H4-PDGFβR t(5;10)(q33;q21)MPDThis study
NPM-ALK t(2;5)(p23;q31)ALCL41
TPM3-ALK t(1;2)(q25;p23)ALCL26
TFG-ALK t(2;3)(p23;q21)ALCL42
ATIC-ALK inv(2)(p23q35)ALCL43
ETV6-TRKC t(12;15)(p13;q25)AML28
ETV6-ARG t(1;12)(q25;p13)AML44
  • a ALL, acute lymphoblastic leukemia, Ph−, Philadelphia chromosome negative; EMS, 8p11 myeloproliferative syndrome; ALCL, anaplastic large cell lymphoma.